TP53 codon 273 mutations can, thus, potentially be an indicator of chemotherapeutic efficacy in astrocytoma, and it may be useful in making astrocytoma treatment decisions. This evidence concerns the gene TP53 and astrocytoma (excluding glioblastoma).